Role of telomeres and telomerase in the pathogenesis of human cancer

Journal of Clinical Oncology

Volumn 21, Issue 10, 2003, Pages 2034-2043

  Hahn, William C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2;

CANCER; CANCER THERAPY; DNA BINDING; DNA DAMAGE; DYSKERATOSIS CONGENITA; ENZYME ACTIVATION; HUMAN; LIFESPAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW; TELOMERE; ENZYMOLOGY; GENETICS; NEOPLASM; PATHOPHYSIOLOGY;

HUMANS; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 0038350026     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.018     Document Type: Review

References (170)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
2. McEachern MJ, Krauskopf A, Blackburn EH: Telomeres and their control. Annu Rev Genet 34:331-358, 2000
3. Meyne J, Ratliff RL, Moyzis RK: Conservation of the human telomere sequence (TTAGGG)n among vertebrates. Proc Natl Acad Sci U S A 86:7049-7053, 1989
4. Moyzis RK, Buckingham JM, Cram LS, et al: A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 85:6622-6626, 1988
5. Henderson ER, Blackburn EH: An overhanging 3′ terminus is a conserved feature of telomeres. Mol Cell Biol 9:345-348, 1989
6. Makarov VL, Hirose Y, Langmore JP: Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 88:657-666, 1997
7. McElligott R, Wellinger RJ: The terminal DNA structure of mammalian chromosomes. Embo J 16:3705-3714, 1997
8. Wright WE, Tesmer VM, Huffman KE, et al: Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev 11:2801-2809, 1997
9. Griffith JD, Comeau L, Rosenfield S, et al: Mammalian telomeres end in a large duplex loop. Cell 97:503-514, 1999
10. de Lange T: Protection of mammalian telomeres. Oncogene 21:532-540, 2002
11. Chong L, van Steensel B, Broccoli D, et al: A human telomeric protein. Science 270:1663-1667, 1995
12. Broccoli D, Smogorzewska A, Chong L, et al: Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet 17:231-235, 1997
13. Bilaud T, Brun C, Ancelin K, et al: Telomeric localization of TRF2, a novel human telobox protein. Nat Genet 17:236-239, 1997
14. van Steensel B, de Lange T: Control of telomere length by the human telomeric protein TRF1. Nature 385:740-743, 1997
15. van Steensel B, Smogorzewska A, de Lange T: TRF2 protects human telomeres from end-to-end fusions. Cell 92:401-413, 1998
16. Karlseder J, Broccoli D, Dai Y, et al: p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283:1321-1325, 1999
17. Stansel RM, de Lange T, Griffith JD: T-loop assembly in vitro involves binding of TRF2 near the 3′ telomeric overhang. Embo J 20:5532-5540, 2001
18. Baumann P, Cech TR: Poll, the putative telomere end-binding protein in fission yeast and humans. Science 292:1171-1175, 2001
19. Sbodio JI, Lodish HF, Chi NW: Tankyrase-2 oligomerizes with tankyrase-1 and binds to both TRF1 (telomere-repeat-binding factor 1) and IRAP (insulin-responsive aminopeptidase). Biochem J 361:451-459, 2002
20. Smith S, Giriat I, Schmitt A, et al: Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 282:1484-1487, 1998
21. Kim S-H, Kamiker P, Campisi J: TIN2, a new regulator of telomere length in human cells. Nat Genet 23:405-412, 1999
22. Li B, Oestreich S, de Lange T: Identification of human Rap1: Implications for telomere evolution. Cell 101:471-483, 2000
23. Zhu XD, Kuster B, Mann M, et al: Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat Genet 25:347-352, 2000
24. Hsu HL, Gilley D, Galande SA, et al: Ku acts in a unique way at the mammalian telomere to prevent end joining. Genes Dev 14:2807-2812, 2000
25. Hsu HL, Gilley D, Blackburn EH, et al: Ku is associated with the telomere in mammals. Proc Natl Acad Sci U S A 96:12454-12458, 1999
26. Bianchi A, de Lange T: Ku binds telomeric DNA in vitro. J Biol Chem 274:21223-21227, 1999
27. Greider CW, Blackburn EH: A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 337:331-337, 1989
28. Nakamura TM, Cech TR: Reversing time: Origin of telomerase. Cell 92:587-590, 1998
29. Meyerson M: Role of telomerase in normal and cancer cells. J Clin Oncol 18:2626-2634, 2000
30. Feng J, Funk WD, Wang SS, et al: The RNA component of human telomerase. Science 269:1236-1241, 1995
31. Mitchell JR, Cheng J, Collins K: A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3′ end. Mol Cell Biol 19:567-576, 1999
32. Nakamura TM, Morin GB, Chapman KB, et al: Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955-959, 1997
33. Meyerson M, Counter CM, Eaton EN, et al: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785-795, 1997
34. Harrington L, Zhou W, McPhail T, et al: Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev 11:3109-3115, 1997
35. Beattie TL, Zhou W, Robinson MO, et al: Functional multimerization of the human telomerase reverse transcriptase. Mol Cell Biol 21:6151-6160, 2001
36. Arai K, Masutomi K, Khurts S, et al: Two independent regions of human telomerase reverse transcriptase are important for its oligomerization and telomerase activity. J Biol Chem 277:8538-8544, 2002
37. Wenz C, Enenkel B, Amacker M, et al: Human telomerase contains two cooperating telomerase RNA molecules. Embo J 20:3526-3534, 2001
38. Lingner J, Hughes TR, Shevchenko A, et al: Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276:561-567, 1997
39. Counter CM, Meyerson M, Eaton EN, et al: The catalytic subunit of yeast telomerase. Proc Natl Acad Sci U S A 94:9202-9207, 1997
40. Nakayama J, Tahara H, Tahara E, et al: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18:65-68, 1998
41. Weinrich SL, Pruzan R, Ma L, et al: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 17:498-502, 1997
42. Kilian A, Bowtell DDL, Abud HE, et al: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 6:2011-2019, 1997
43. Armbruster BN, Banik SS, Guo C, et al: N-terminal domains of the human telomerase catalytic subunit required for enzyme activity in vivo. Mol Cell Biol 21:7775-7786, 2001
44. Counter CM, Hahn WC, Wei W, et al: Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A 95:14723-14728, 1998
45. Beattie TL, Zhou W, Robinson MO, et al: Polymerization defects within human telomerase are distinct from telomerase RNA and TEP1 binding. Mol Biol Cell 11:3329-3340, 2000
46. Bryan TM, Goodrich KJ, Cech TR: Telomerase RNA bound by protein motifs specific to telomerase reverse transcriptase. Mol Cell 6:493-499, 2000
47. Harrington L, McPhail T, Mar V, et al: A mammalian telomerase-associated protein. Science 275:973-977, 1997
48. Holt SE, Aisner DL, Baur J, et al: Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 13:817-826, 1999
49. Liu Y, Snow BE, Hande MP, et al: Telomerase-associated protein TEP1 is not essential for telomerase activity or telomere length maintenance in vivo. Mol Cell Biol 20:8178-8184, 2000
50. McClintock B: The stability of broken ends of chromosomes in Zea mays. Genetics 26:234-282, 1941
51. Blackburn EH, Chiou SS: Non-nucleosomal packaging of a tandemly repeated DNA sequence at termini of extrachromosomal DNA coding for rRNA in Tetrahymena. Proc Natl Acad Sci U S A 78:2263-2267, 1981
52. Yu GL, Bradley JD, Attardi LD, et al: In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature 344:126-132, 1990
53. Blasco MA, Lee HW, Hande MP, et al: Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91:25-34, 1997
54. Hahn WC, Stewart SA, Brooks MW, et al: Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5:1164-1170, 1999
55. Blackburn EH: Telomere states and cell fates. Nature 408:53-56, 2000
56. Kirk KE, Harmon BP, Reichardt IK, et al: Block in anaphase chromosome separation caused by a telomerase template mutation. Science 275:1478-1481, 1997
57. Kim MM, Rivera MA, Botchkina IL, et al: A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci U S A 98:7982-7987, 2001
58. Guiducci C, Cerone MA, Bacchetti S: Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability. Oncogene 20:714-725, 2001
59. McEachem MJ, Iyer S, Fulton TB, et al: Telomere fusions caused by mutating the terminal region of telomeric DNA. Proc Natl Acad Sci U S A 97:11409-11414, 2000
60. de Lange T, Shiue L, Myers RM, et al: Structure and variability of human chromosome ends. Mol Cell Biol 10:518-527, 1990
61. Zhu J, Wang H, Bishop JM, et al: Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci U S A 96:3723-3728, 1999
62. Harley CB, Kim NW, Prowse KR, et al: Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol 59:307-315, 1994
63. Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res 25:585-621, 1961
64. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015, 1994
65. Allsopp RC, Vaziri H, Patterson C, et al: Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 89:10114-10118, 1992
66. Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345:458-460, 1990
67. Counter CM, Avilion AA, Le Feuvre CE, et al: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11:1921-1929, 1992
68. Counter CM, Hirte HW, Bacchetti S, et al: Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci U S A 91:2900-2904, 1994
69. Hastie ND, Dempster M, Dunlop MG, et al: Telomere reduction in human colorectal carcinoma and with ageing. Nature 346:866-868, 1990
70. Akiyama M, Hoshi Y, Sakurai S, et al: Changes of telomere length in children after hematopoietic stem cell transplantation. Bone Marrow Transplant 21:167-171, 1998
71. Wynn RF, Cross MA, Hatton C, et al: Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 351:178-181, 1998
72. Bodnar AG, Ouellette M, Frolkis M, et al: Extension of life-span by introduction of telomerase into normal human cells. Science 279:349-352, 1998
73. Vaziri H, Benchimol S: Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 8:279-282, 1998
74. Yang J, Chang E, Cherry AM, et al: Human endothelial cell life extension by telomerase expression. J Biol Chem 274:26141-26148, 1999
75. Zhang X, Mar V, Zhou W, et al: Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13:2388-2399, 1999
76. Herbert B, Pitts AE, Baker SI, et al: Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci U S A 96:14276-14281, 1999
77. Mukai S, Kondo Y, Koga S, et al: 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 60:4461-4467, 2000
78. Damm K, Hemmann U, Garin-Chesa P, et al: A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 20:6958-6968, 2001
79. Sedivy JM: Can ends justify the means? Telomeres and the mechanisms of replicative senescence and immortalization in mammalian cells. Proc Natl Acad Sci U S A 95:9078-9081, 1997
80. Shay JW, Wright WE, Werbin H: Defining the molecular mechanisms of human cell immortalization. Biochim Biophys Acta 1072:1-7, 1991
81. Ali SH, DeCaprio JA: Cellular transformation by SV40 large T antigen: Interaction with host proteins. Semin Cancer Biol 11:15-23, 2001
82. Wei W, Sedivy JM: Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures. Exp Cell Res 253:519-522, 1999
83. Shay JW, Wright WE: Quantitation of the frequency of immortalization of normal human diploid fibroblasts by SV40 large T-antigen. Exp Cell Res 184:109-118, 1989
84. Halvorsen TL, Leibowitz G, Levine F: Telomerase activity is sufficient to allow transformed cells to escape from crisis. Mol Cell Biol 19:1864-1870, 1999
85. Dickson MA, Hahn WC, Ino Y, et al: Human keratinocytes that express hTERT and also evade a p16ink4a-enforced lifespan limit become immortal while retaining normal growth and differentiation characteristics. Mol Cell Biol 20:1436-1447, 2000
86. Kiyono T, Foster SA, Koop JI, et al: Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396:84-88, 1998
87. Ramirez RD, Morales CP, Herbert BS, et al: Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev 15:398-403, 2001
88. DiRenzo J, Signoretti S, Nakamura N, et al: Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 62:89-98, 2002
89. Karlseder J, Smogorzewska A, de Lange T: Senescence induced by altered telomere state, not telomere loss. Science 295:2446-2449, 2002
90. Bryan TM, Englezou A, Gupta J, et al: Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14:4240-4248, 1995
91. Murnane JP, Sabatier L, Marder BA, et al: Telomere dynamics in an immortal human cell line. EMBO J 13:4953-4962, 1994
92. Lundblad V, Szostak JW: A mutant with a defect in telomere elongation leads to senescence in yeast. Cell 57:633-643, 1989
93. Teng SC, Zakian VA: Telomere-telomere recombination is an efficient bypass pathway for telomere maintenance in Saccharomyces cerevisiae. Mol Cell Biol 19:8083-8093, 1999
94. Dunham MA, Neumann AA, Fasching CL, et al: Telomere maintenance by recombination in human cells. Nat Genet 26:447-450, 2000
95. Perrem K, Colgin LM, Neumann AA, et al: Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 21:3862-3875, 2001
96. Ford LP, Zou Y, Pongracz K, et al: Telomerase can inhibit the recombination-based pathway of telomere maintenance in human cells. J Biol Chem 276:32198-32203, 2001
97. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791, 1997
98. Hathcock KS, Weng NP, Merica R, et al: Cutting edge: Antigen-dependent regulation of telomerase activity in murine T cells. J Immunol 160:5702-5706, 1998
99. Broccoli D, Young JW, de Lange T: Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A 92:9082-9086, 1995
100. Counter CM, Gupta J, Harley CB, et al: Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85:2315-2320, 1995
101. Harle-Bachor C, Boukamp P: Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci U S A 93:6476-6481, 1996
102. Yasumoto S, Kunimura C, Kikuchi K, et al: Telomerase activity in normal human epithelial cells. Oncogene 13:433-439, 1996
103. Hiyama E, Hiyama K, Tatsumoto N, et al: Telomerase activity in human intestine. Int J Oncol 9:453-458, 1996
104. Yui J, Chiu CP, Lansdorp PM: Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood 91:3255-3262, 1998
105. Hiyama E, Hiyama K: Clinical utility of telomerase in cancer. Oncogene 21:643-649, 2002
106. Land H, Parada LF, Weinberg RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596-602, 1983
107. Ruley H: Adenovirus early region IA enables viral and cellular transforming genes to transform primary cells in culture. Nature 304:602-606, 1983
108. Sager R, Tanaka K, Cau CC, et al: Resistance of human cells to tumorigenesis induced by cloned transforming genes. Proc Natl Acad Sci U S A 80:7601-7605, 1983
109. Campisi J: From cells to organisms: Can we learn about aging from cells in culture. Exp Gerontol 36:607-618, 2001
110. Sager R: Senescence as a mode of tumor suppression. Environ Health Perspect 93:59-62, 1991
111. Elenbaas B, Spirio L, Koerner F, et al: Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15:50-65, 2001
112. Hahn WC, Counter CM, Lundberg AS, et al: Creation of human tumor cells with defined genetic elements. Nature 400:464-468, 1999
113. Lundberg AS, Randell SH, Stewart SA, et al: Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 21:4577-4586, 2002
114. Rich JN, Guo C, McLendon RE, et al: A genetically tractable model of human glioma formation. Cancer Res 61:3556-3560, 2001
115. 115: Yu J, Boyapati A, Rundell K: Critical role for SV40 small-t antigen in human cell transformation. Virology 290:192-198, 2001
116. MacKenzie KL, Franco S, Naiyer AJ, et al: Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene 21:4200-4211, 2002
117. Wright WE, Shay JW: Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology. Nat Med 6:849-851, 2000
118. Chadeneau C, Siegel P, Harley CB, et al: Telomerase activity in normal and malignant murine tissues. Oncogene 11:893-898, 1995
119. Prowse KR, Greider CW: Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci U S A 92:4818-4822, 1995
120. Kipling D, Cooke HJ: Hypervariable ultra-long telomeres in mice. Nature 347:400-402, 1990
121. Lee HW, Blasco MA, Gottlieb GJ, et al: Essential role of mouse telomerase in highly proliferative organs. Nature 392:569-574, 1998
122. Greenberg RA, Chin L, Femino A, et al: Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 97:515-525, 1999
123. Gonzalez-Suarez E, Samper E, Flores JM, et al: Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 26:114-117, 2000
124. Artandi SE, Chang S, Lee S-L, et al: Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406:461-465, 2000
125. Rudolph KL, Millard M, Bosenberg MW, et al: Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28:155-159, 2001
126. Falchetti ML, Pallini R, Larocca LM, et al: Telomerase expression in intracranial tumours: Prognostic potential for malignant gliomas and meningiomas. J Clin Pathol 52:234-236, 1999
127. Langford LA, Piatyszek MA, Xu R, et al: Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol 28:416-420, 1997
128. Matthews P, Jones CJ, Skinner J, et al: Telomerase activity and telomere length in thyroid neoplasia: Biological and clinical implications. J Pathol 194:183-193, 2001
129. Pearson AS, Chiao P, Zhang L, et al: The detection of telomerase activity in patients with adenocarcinoma of the pancreas by fine needle aspiration. Int J Oncol 17:381-385, 2000
130. Lancelin F, Anidjar M, Villette JM, et al: Telomerase activity as a potential marker in preneoplastic bladder lesions. Br J Urol Int 85:526-531, 2000
131. Wisman GB, Knol AJ, Helder MN, et al: Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer 91:658-664, 2001
132. Zheng PS, Iwasaka T, Zhang ZM, et al: Telomerase activity in Papanicolaou smear-negative exfoliated cervical cells and its association with lesions and oncogenic human papillomaviruses. Gynecol Oncol 77:394-398, 2000
133. Tang R, Cheng AJ, Wang JY, et al: Close correlation between telomerase expression and adenomatous polyp progression in multistep colorectal carcinogenesis. Cancer Res 58:4052-4054, 1998
134. Rahat MA, Lahat N, Gazawi H, et al: Telomerase activity in patients with transitional cell carcinoma: A preliminary study. Cancer 85:919-924, 1999
135. Koyanagi Y, Kobayashi D, Yajima T, et al: Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemic cells. Anticancer Res 20:773-778, 2000
136. Hiyama E, Gollahon L, Kataoka T, et al: Telomerase activity in human breast tumors. J Natl Cancer Inst 88:116-122, 1996
137. Fang DC, Young J, Luo YH, et al: Detection of telomerase activity in biopsy samples of colorectal cancer. J Gastroenterol Hepatol 14:328-332, 1999
138. Kolquist KA, Ellisen LW, Counter CM, et al: Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 19:182-186, 1998
139. Stewart SA, Hahn WC, O'Connor BF, et al: Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 99:12606-12611, 2002
140. Gonzalez-Suarez E, Samper E, Ramirez A, et al: Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 20:2619-2630, 2001
141. Artandi SE, Alson S, Tietze MK, et al: Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci U S A 99:8191-8196, 2002
142. Dokal I: Dyskeratosis congenita in all its forms. Br J Haematol 110:768-779, 2000
143. Mitchell JR, Wood E, Collins K: A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402:551-555, 1999
144. Vulliamy T, Marrone A, Goldman F, et al: The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413:432-435, 2001
145. Liu K, Hodes RJ, Weng N: Cutting edge: Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J Immunol 166:4826-4830, 2001
146. Ulaner GA, Hu JF, Vu TH, et al: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 58:4168-4172, 1998
147. Meeker AK, Gage WR, Hicks JL, et al: Telomere length assessment in human archival tissues: Combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol 160:1259-1268, 2002
148. Pascolo E, Wenz C, Lingner J, et al: Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 277:15566-15572, 2002
149. Fang G, Cech TR: The beta subunit of Oxytricha telomere-binding protein promotes G-quartet formation by telomeric DNA. Cell 74:875-885, 1993
150. Koeppel F, Riou JF, Laoui A, et al: Ethidium derivatives bind to G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes. Nucleic Acids Res 29:1087-1096, 2001
151. Mergny JL, Mailliet P, Lavelle F, et al: The development of telomerase inhibitors: The G-quartet approach. Anticancer Drug Des 14:327-339, 1999
152. Fang G, Cech TR: Characterization of a G-quartet formation reaction promoted by the beta-subunit of the Oxytricha telomere-binding protein. Biochemistry 32:11646-11657, 1993
153. Sharma HW, Hsiao R, Narayanan R: Telomerase as a potential molecular target to study G-quartet phosphorothioates. Antisense Nucleic Acid Drug Dev 6:3-7, 1996
154. Neidle S, Parkinson G: Telomere maintenance as a target for anticancer drug therapy. Nat Rev Drug Discovery 1:383-393, 2002
155. Zahler AM, Williamson JR, Cech TR, et al: Inhibition of telomerase by G-quartet DNA structures. Nature 350:718-720, 1991
156. Hodes R: Molecular targeting of cancer: Telomeres as targets. Proc Natl Acad Sci U S A 98:7649-7651, 2001
157. Hahn WC, Meyerson M: Telomerase activation, cellular immortalization and cancer. Ann Med 33:123-129, 2001
158. Gu J, Kagawa S, Takakura M, et al: Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 60:5359-5364, 2000
159. Majumdar AS, Hughes DE, Lichtsteiner SP, et al: The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 8:568-578, 2001
160. Koga S, Hirohata S, Kondo Y, et al: FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res 21:1937-1943, 2001
161. Komata T, Kondo Y, Kanzawa T, et al: Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61:5796-5802, 2001
162. Abdul-Ghani R, Ghana P, Matouk I, et al: Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2:539-544, 2000
163. Nair SK, Heiser A, Boczkowski D, et al: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6:1011-1017, 2000
164. Arai J, Yasukawa M, Ohminami H, et al: Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97:2903-2907, 2001
165. Vonderheide RH, Hahn WC, Schultze JL, et al: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673-679, 1999
166. Vonderheide RH, Schultze JL, Anderson KS, et al: Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 61:8366-8370, 2001
167. Vonderheide RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21:674-679, 2002
168. Goytisolo FA, Samper E, Martin-Caballero J, et al: Short telomeres resuit in organismal hypersensitivity to ionizing radiation in mammals. J Exp Med 192:1625-1636, 2000
169. Wong KK, Chang S, Weiler SR, et al: Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet 26:85-88, 2000
170. Lee KH, Rudolph KL, Ju YJ, et al: Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci U S A 98:3381-3386, 2001